PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, United States.\', \'HDT Bio, Seattle, United States.\', \'Rocky Mountain Veterinary Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, United States.\', \'Department of Microbiology, University of Washington School of Medicine, Seattle, United States.\', \'Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington School of Medicine, Seattle, United States.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.7554/eLife.75537e75537
?:hasPublicationType
?:journal
  • eLife
is ?:pmid of
?:pmid
?:pmid
  • 35191378
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 7.121
?:rankingScore_hIndex
  • 74
?:title
  • SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
?:type
?:year
  • 2022

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/35191378>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/35191378>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all